Virginia Kaklamani, MD

A panel of experts offer future perspectives in HR+ breast cancer.

A panel of experts offer perspectives in sequencing ADC-Based therapies in HR+ breast cancer.

A panel of experts discuss ADC-based treatment strategies in HR+ Breast cancer.

A panel of experts discuss treatment advancements targeting the PI3K/AKT pathway in HR+ Breast Cancer.

A panel of experts discuss navigating 2L treatment strategies.

A panel of experts offer perspectives in navigating treatment strategies with CDK4/6 inhibitors.

A panel of experts discuss treatment updates in regards to CDK4/6 inhibitors.

A panel of experts discuss the potential of individual tumor sequencing with bespoke testing methodologies.

A panel of experts give perspectives on optimizing biomarker testing in Advanced HR+/HER2- Breast Cancer.

A panel of experts discuss advancements in adjuvant therapy for early-stage breast cancer.

Expert breast oncologists examine adjuvant therapy approaches for early-stage hormone receptor-positive breast cancer, emphasizing the distinct treatment strategies and outcomes observed in pre- and post-menopausal patient populations.

Leading oncologists explore optimal biomarker testing strategies for early-stage breast cancer, examining the comparative advantages of tissue and liquid biopsies to guide personalized treatment decisions.

Virginia Kaklamani, MD, and Elizabeth Diaz, PA-C, share advice for providers managing patients with HR+/HER2- metastatic breast cancer.

Experts highlight some remaining unmet needs in the treatment and management of patients with HR+/HER2- metastatic breast cancer.

Elizabeth Diaz, PA-C, details how she approaches adverse event management in patients undergoing treatment for HR+/HER2- metastatic breast cancer.

Dr Virginia Kaklamani explains how she selects among the available treatment regimens for her patients with HR+/HER2= metastatic breast cancer.

Virginia Kaklamani, MD, and Elizabeth Diaz, PA-C, Diaz review the available safety and efficacy data from the TROPiCS-02 trial on the use of antibody drug conjugate sacituzumab govitecan for the treatment of HR+/HER2- metastatic breast cancer.

Virginia Kaklamani, MD, presents the case of a 56-year-old postmenopausal woman diagnosed with ER+/HER2- metastatic breast cancer for discussion.

Key opinion leaders review the use of antibody-drug conjugates (ADCs) in treating HR+/HER2- metastatic breast cancer, and how they counsel patients before starting them on therapy with an ADC.

Experts discuss the complexity of defining endocrine resistance in patients with HR+/HER2- metastatic breast cancer and the options for treatment.

Virginia Kaklamani, MD, presents the case of a 47-year-old premenopausal woman diagnosed with HR+/HER2- metastatic breast cancer for discussion.

Virginia Kaklamani, MD, and Elizabeth Diaz, PA-C, offer an overview of HR+/HER2- metastatic breast cancer and detail the standard-of-care first-line therapy options.